SOURCE: Pegasus Pharmaceuticals Inc.

April 18, 2011 17:24 ET

Pegasus Acquires U.S. Patent for Its HeartVue 6S Screening Device; Appoints Two European Distributors

PALM BEACH GARDENS, FL--(Marketwire - Apr 18, 2011) - Pegasus/HeartView LLC (PINKSHEETS: PGUZ) today announced that they have acquired a U.S. Patent Number #US 7,519,416, titled "Diagnostic Method Utilizing Standard Lead ECG Signals" for its HeartVue 6S Screening Device.

This development will now initiate procedures to acquire FDA approval prior to marketing efforts of the system in the United States. The HeartVue 6S System is an advanced technology that analyzes low amplitude ECG oscillations (ECG dispersion mapping) and reports them as myocardial micro-alternation indexes (MMI). The HeartVue 6S System provides a non-invasive assessment of heart disease in 30 seconds, utilizing only 4 limb electrodes. The results are then presented as a color-coded, three dimensional digital heart map, which reflects electrical dispersions.

After acquiring a CE Mark Approval for the marketing of the 6S Screening Device in Europe, the Company has now subsequently appointed two distributors to roll out marketing/sales efforts in their respective territories.

United Kingdom:
Efficiency Technologies Limited,
Unit 3, Blackhill Drive, Wolverton Mill,
Milton Keynes, Buckinghamshire, MK 12 5TS United Kingdom
Tel: +44 (0) 845 299 7898

Cypress, Turkey, Greece, Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, UAE, Syria, Lebanon, Israel:
Despina Rousseau Aim Design & Art Ltd.
Nicosia, Cyprus
Tel: +30 210 983 9217 +30 697 232 4108 +30 694 390 6605

For more information, contact Daniel P. Kesonen, Chairman & CEO of Pegasus Pharmaceuticals Inc., Palm Beach Gardens, FL at (561) 626-9901. Email: Visit the Company's website:

We seek Safe Harbor.

Contact Information